Intensive Cancer Screening After Cryptogenic Stroke

Recruiting now · Not applicable

Conditions studied: Occult Cancer

In brief

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

Key facts

Study ID

NCT05733416

Run by

Ottawa Hospital Research Institute

People needed

45

Starts

2023-09-01

Expected to finish

2027-01-01

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults ≥18 years
• presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
• patient or delegate willing and able to provide informed consent.

You may not qualify if…

• contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
• active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)

Where it is running

• The Ottawa Hospital — Ottawa, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.